Acura Pharmaceuticals Inc. has announced plans for a new clinical study involving their drug candidate LTX-03, a formulation combining hydrocodone bitartrate and acetaminophen. This decision follows a recent meeting with the US Food and Drug Administration (FDA), where further development requirements were discussed. The study, designated AP-LTX-310, will compare a single tablet dose of LTX-03 to a single FDA Reference Standard drug under fed and fasted conditions. LTX-03 utilizes Acura's LIMITx technology, designed to lower peak drug blood concentrations as additional tablets are consumed. FDA has agreed to potentially describe the unique pharmacokinetic characteristics of LTX-03 in its labeling, subject to a New Drug Application (NDA) review. Acura Pharmaceuticals is also considering plans to support lower dosage strengths of LTX-03 for the NDA submission or after approval.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.